LUNG CANCER

John V. Heymach, MD, PhD, reviewed the case of a 73-year-old women with extensive-stage small cell lung cancer during a virtual Case Based Peer Perspective event.

Edward B. Garon, MD, discusses an exciting new agent, or class of agents, that are under evaluation as treatment of patients with non-small cell lung cancer.

Experts in lung oncology review 3 clinical cases and discuss individualized treatment approaches for each patient.

Vivek Subbiah, MD, discusses the implications of the phase 1/2 LIBRETTO-001 study, which evaluated selpercatinib as treatment of patients with RET fusion-positive non–small cell lung cancer.

The FDA has granted approval to a generic form of the chemotherapy agent pemetrexed, which is indicated for intravenous administration in patients with locally advanced or metastatic nonsquamous non–small cell lung cancer that have not progressed following 4 cycles of first-line platinum-based chemotherapy.

The FDA accepted a New Drug Application for tepotinib and granted it priority review for the treatment of adult patients with metastatic non–small cell lung cancer who harbor a mutation that leads to mesenchymal-epithelial transition exon 14 skipping, as detected by an FDA-approved test.

A quality improvement tool called “Improving Care Coordination: A Model for Lung Cancer” released by the Association of Community Cancer Centers is a model framework to be used by cancer care providers to improve care coordination for patients with lung cancer who are covered by Medicaid.